

A6-556-T025

Monoclonal Antibody to HLA-A2 Alexa Fluor® 647 conjugated (25 tests)

Clone:	BB7.2
Isotype:	Mouse IgG2b
Specificity:	The antibody BB7.2 recognizes an epitope at the C-terminus of alpha-2 helix and a turn on one of the underlying beta strands within the human HLA-A2 histocompatibility antigen.
Regulatory Status:	RUO
Immunogen:	HLA-A2 solubilised by papain
Species Reactivity:	Human
Preparation:	The purified antibody is conjugated with Alexa Fluor® 647 under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
Storage Buffer:	The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.
Storage / Stability:	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Usage:	The reagent is designed for Flow Cytometry analysis of human blood cells using 5 µl reagent / 100 µl of whole blood or 10 ⁶ cells in a suspension. The content of a vial (0.125 ml) is sufficient for 25 tests.
Expiration:	See vial label
Lot Number:	See vial label
Background:	HLA-A2 (44 kDa) is the most frequent HLA-A allele in human ethnic populations. HLA-A, together with HLA-B and HLA-C, represent human HLA class I major histocompatibility (MHC) antigens. These intrinsic membrane glycoproteins are expressed on nucleated cells and noncovalently associate with an invariant beta2 microglobulin. They carry foreign determinants important for immune recognition by cytotoxic T cells, thus important for anti-viral and anti-tumour defence.

For laboratory research only, not for drug, diagnostic or other use.

**Antibodies****References:**

- *Parham P, Brodsky FM: Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. *Hum Immunol.* 1981 Dec;3(4):277-99.
- *Pious D, Krangel MS, Dixon LL, Parham P, Strominger JL: HLA antigen structural gene mutants selected with an allospecific monoclonal antibody. *Proc Natl Acad Sci U S A.* 1982 Dec;79(24):7832-6.
- *Krangel MS, Taketani S, Pious D, Strominger JL: HLA-A2 mutants immunoselected in vitro. Definition of residues contributing to an HLA-A2-specific serological determinant. *J Exp Med.* 1983 Jan 1;157(1):324-36."
- *Taketani S, Krangel MS, Pious D, Strominger JL: Structural analysis of HLA-A2 antigen from immunoselected mutant 8.6.1: further definition of an HLA-A2-specific serological determinant. *J Immunol.* 1983 Dec;131(6):2935-8. "
- *Brenner MB, McLean J, Yang SY, van der Poel JJ, Pious D, Strominger JL: Clonal T lymphocyte recognition of the fine structure of the HLA-A2 molecule. *J Immunol.* 1985 Jul;135(1):384-90.
- *Scornik JC: HLA-A2 epitopes recognized by alloantibodies from broadly sensitized patients. *Hum Immunol.* 1987 Apr;18(4):277-85.
- *Santos-Aguado J, Barbosa JA, Biro PA, Strominger JL: Molecular characterization of serologic recognition sites in the human HLA-A2 molecule. *J Immunol.* 1988 Oct 15;141(8):2811-8."
- *Natali PG, Nicotra MR, Bigotti A, Ventura I, Marcenaro L, Giacomini P, Russo C: Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. *Proc Natl Acad Sci U S A.* 1989 Sep;86(17):6719-23.
- *Hogan KT, Brown SL: Localization and characterization of serologic epitopes on HLA-A2. *Hum Immunol.* 1992 Mar;33(3):185-92.
- *Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ, Kast WM: Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. *Eur J Immunol.* 1993 Jun;23(6):1215-9.
- *Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ: HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. *J Immunol.* 1993 Nov 15;151(10):5481-91.
- *Barouch D, Davenport M, McMichael A, Reay P: A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide. *Int Immunol.* 1995 Oct;7(10):1599-605.
- *Lee L, Loftus D, Appella E, Margulies DH, Mage M: A recombinant single-chain HLA-A2.1 molecule, with a cis active beta-2-microglobulin domain, is biologically active in peptide binding and antigen presentation. *Hum Immunol.* 1996 Aug;49(1):28-37.
- *Forero L, Zwirner NW, Fink CW, Fernández-Viñuela MA, Stastny P: Juvenile arthritis, HLA-A2 and binding of DEK oncogene-peptides. *Hum Immunol.* 1998 Jul;59(7):443-50.
- *Verdegaal EM, Huinink DB, Hoogstraten C, Marijnissen AK, Gorsira MB, Claas FH, Osanto S: Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient. *Hum Immunol.* 1999 Dec;60(12):1195-206.
- *Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP: Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. *Obstet Gynecol.* 2000 Sep;96(3):422-30.
- *Liang B, Zhu L, Liang Z, Weng X, Lu X, Zhang C, Li H, Wu X: A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China. *Cell Mol Immunol.* 2006 Dec;3(6):453-8.
- *And many other.

For laboratory research only, not for drug, diagnostic or other use.



Antibodies

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

This product is provided under an agreement between Molecular Probes, Inc. (a wholly owned subsidiary of Invitrogen Corporation), and Exbio Praha, a.s., and the manufacture, use, sale or import of this product may be subject to one or more U.S. patents, pending applications, and corresponding non-U.S. equivalents, owned by Molecular Probes, Inc. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity), including use in flow cytometry that does not utilize a bead based array, but excluding use in combination with microarrays or High Content Screening. The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Molecular Probes, Inc., Business Development, 29851 Willow Creek Road, Eugene, OR 97402, USA, Tel: (541) 465-8300. Fax: (541) 335-0504.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz